PALI
Earnings in 7 days · May 11, 2026 · After close
Signal
Mixed11
Price
1
Move+6.23%Strong session
Volume
1
Volume0.5× avgLight volume
Technical
1
RSIRSI 46Momentum negative
PRICE
Prev Close
1.99
Open
2.00
Day Range1.98 – 2.13
1.98
2.13
52W Range0.53 – 2.86
0.53
2.86
68% of range
VOLUME & SIZE
Avg Volume
4.0M
FUNDAMENTALS
P/E Ratio
-7.0x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.07
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 29.0 · FCF negative
Neutral
Key MetricsTTM
Market Cap$354.10M
Revenue TTM$0.00
Net Income TTM-$16.78M
Free Cash Flow-$10.85M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-47.8%
Return on Assets-12.5%
Debt / Equity0.00
Current Ratio28.95
EPS TTM$-0.30

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
50/100
Liquidity
28.95Strong
Leverage
0.00Strong
Coverage
-1805.6xConcern
ROE
-47.8%Concern
ROIC
-13.9%Concern
Cash
$133MStrong
ANALYST COVERAGE3 analysts
BUY
-29.0%downside to target
Buy
3100%
3 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
2 of 4 signals bullish
5/10
Technicals
RSI RangeRSI 46 — Bearish momentum
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 28.95 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 5, 2026
Tomorrow
DEx-Dividend DateAug 2, 2026
In 90 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 22.1%

+9.3% vs SMA 50 · +33.4% vs SMA 200

Momentum

RSI45.9
Neutral territory
MACD+0.06
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$2.86+35.3%
Current
$2.11
EMA 50
$2.00-5.3%
EMA 200
$1.55-26.5%
52W Low
$0.5300-74.9%
52-Week RangeMid-range
$0.530068th %ile$2.86
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 6 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$12.1M
$12.1M$12.1M
-$0.54
±50%
High6
FY2026(current)
$27.9M
$27.9M$27.9M
+129.4%-$0.20
±47%
High6
FY2027
$47.7M
$47.7M$47.7M
+71.2%-$0.24
±33%
High6
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryPALI
Last 8Q
-1.0%avg beat
Beat 4 of 8 quartersMissed 4 Estimates rising
+4%
Q2'24
-13%
Q3'24
+31%
Q4'24
+65%
Q1'25
+44%
Q2'25
-21%
Q3'25
-19%
Q4'25
-100%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Maxim GroupBuy
Mar 30
UPGRADE
Insider Activity
SEC Filings →
4 Buys/2 SellsNet Buying
Jones Mitchell Lawr…Chief Medical …
$3K
Feb 12
SELL
Finley John DavidDir
$7K
Feb 12
SELL
Williams Donald All…Dir
$8K
Jan 16
BUY
Williams Donald All…Dir
$9K
Jan 9
BUY
Williams Donald All…Dir
$5K
May 28
BUY
Finley John DavidDir
$5K
May 24
BUY
Financials

INSTITUTIONAL OWNERSHIP

1
abrdn plc
663K
2
Simplify Asset Management Inc.
350K
3
Total Clarity Wealth Management, Inc.
27K
4
COMMONWEALTH EQUITY SERVICES, LLC
17K
5
RFG Advisory, LLC
12K
6
FNY Investment Advisers, LLC
10K
7
Avion Wealth
0
8
PERCEPTIVE ADVISORS LLC
12.1M
News & Activity

PALI News

20 articles · 4h ago

About

No description available.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Kenneth Carter
Mitchell Lawrence JonesPresident & Chief Medical Officer
Ryker WillieSenior Vice President of Finance & Corporate Controller
Sharon SkareVice President & Global Head of Clinical Operations